In MDS patient cohorts including all disease subtypes, TET2 mutations were found to be associated with shorter OS after hematopoietic stem cell transplantation and lower response rate to hypomethylating agents [9,52,53]. The gene discussed is TET2; the disease is myelodysplastic syndrome.